Leucine Supplementation in Elderly Men

This study has been completed.
Information provided by:
Maastricht University Medical Center
ClinicalTrials.gov Identifier:
First received: December 11, 2008
Last updated: NA
Last verified: December 2008
History: No changes posted
In the present study the investigators aim to determine whether leucine supplementation can augment muscle mass and strength and improve body composition in healthy elderly men

Condition Intervention Phase
Dietary Supplement: placebo
Dietary Supplement: leucine
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: The Influence of Leucine Supplementation on Body Composition and Muscle Characteristics in Healthy Elderly

Resource links provided by NLM:

Further study details as provided by Maastricht University Medical Center:

Primary Outcome Measures:
  • muscle mass and body composition [ Time Frame: before and after 12 wk intervention ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • muscle strength [ Time Frame: before and after 12 wk intervention ] [ Designated as safety issue: No ]

Enrollment: 29
Study Start Date: January 2007
Study Completion Date: December 2008
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
daily leucine supplementation
Dietary Supplement: leucine
daily leucine capsules with each main meal
Placebo Comparator: 2
daily placebo supplementation
Dietary Supplement: placebo
wheat meal capsules with each main meal


Ages Eligible for Study:   65 Years to 85 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • living independently

Exclusion Criteria:

  • Diabetes cardiovascular disease orthopedic limitations history of resistance training in past 5 years
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00807508

Maastricht University Medical Centre
Maastricht, Netherlands, 6200 MD
Sponsors and Collaborators
Maastricht University Medical Center
Principal Investigator: Luc JC van Loon, PhD Maastricht University Medical Center
  More Information

No publications provided by Maastricht University Medical Center

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Luc JC van Loon, PhD, MaastrichtUMC
ClinicalTrials.gov Identifier: NCT00807508     History of Changes
Other Study ID Numbers: MEC 06-3-062A 
Study First Received: December 11, 2008
Last Updated: December 11, 2008
Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Additional relevant MeSH terms:
Muscular Atrophy
Nervous System Diseases
Neurologic Manifestations
Neuromuscular Manifestations
Pathological Conditions, Anatomical
Signs and Symptoms

ClinicalTrials.gov processed this record on February 09, 2016